



PRIOR AUTHORIZATION CRITERIA

Generic/Brand: **Retin A/ tretinoin**

DESCRIPTION:

Retin-A Gel, Cream and Liquid containing tretinoin are used for the topical treatment of acne vulgaris.

INDICATIONS/RECOGNIZED USES:

Retin-A is indicated for the topical applications in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

DOSAGE:

Retin A Gel, Cream or Liquid should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Liquid: The liquid may be applied using a fingertip, gauze pad or cotton swab. If gauze or cotton is employed, care should be taken not to over saturate it to the extent that the liquid would run into areas where treatment is not intended. Gel: Excessive application results in "pilling" of the gel, which minimizes the likelihood of over application by the patient. Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment.

CLINICAL SIDE EFFECTS:

The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of RETIN-A

Requirements for Approval: Treatment for one of the following only

- Acne Vulgaris
- Actinic Keratosis
- Acne Rosacea
- Hyperpigmentation of face
- Keratosis follicularis
- Lamellar ichthyosis
- Psoriasis
- Veruca plana
- Skin Cancer/pre-cancerous lesions

LENGTH OF APPROVAL:

6 months; 1 year for Acne

- 1) Denial of medication to patients over 29 y/o if they do not present the above diagnosis
- 2) Denial of medication to patients for treatment of wrinkles or solar elastosis.